AR and carcinoma: AR antagonism is highly effective in counteracting AR signaling thus altering associated metabolic programs, but tumors evolve by acquiring androgen-independent AR activation in adenocarcinoma or bypassing AR requirement through transdifferentiation to more aggressive and lethal AR-indifferent carcinomas (33).